LLY

997.31

-0.83%↓

JNJ

227.5

-1.14%↓

ABBV

210.41

-0.16%↓

UNH

391.62

-2.08%↓

AZN

181.74

-1.93%↓

LLY

997.31

-0.83%↓

JNJ

227.5

-1.14%↓

ABBV

210.41

-0.16%↓

UNH

391.62

-2.08%↓

AZN

181.74

-1.93%↓

LLY

997.31

-0.83%↓

JNJ

227.5

-1.14%↓

ABBV

210.41

-0.16%↓

UNH

391.62

-2.08%↓

AZN

181.74

-1.93%↓

LLY

997.31

-0.83%↓

JNJ

227.5

-1.14%↓

ABBV

210.41

-0.16%↓

UNH

391.62

-2.08%↓

AZN

181.74

-1.93%↓

LLY

997.31

-0.83%↓

JNJ

227.5

-1.14%↓

ABBV

210.41

-0.16%↓

UNH

391.62

-2.08%↓

AZN

181.74

-1.93%↓

Search

Guardant Health Inc

Open

BrancheGesundheitswesen

92.8 -5.79

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

92.27

Max

98.97

Schlüsselkennzahlen

By Trading Economics

Einkommen

16M

-112M

Verkäufe

20M

302M

EPS

-0.45

Gewinnspanne

-37.152

Angestellte

2,490

EBITDA

18M

-101M

Empfehlungen

By TipRanks

Empfehlungen

Starkes Kaufsignal

12-Monats-Prognose

+30.88% upside

Dividenden

By Dow Jones

Nächstes Ergebnis

29. Juli 2026

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

737M

13B

Vorheriger Eröffnungskurs

98.59

Vorheriger Schlusskurs

92.8

Nachrichtenstimmung

By Acuity

50%

50%

171 / 346 Ranking in Healthcare

Technischer Score

By Trading Central

Vertrauen

Very Strong Bearish Evidence

Guardant Health Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

14. Mai 2026, 22:44 UTC

Akquisitionen, Fusionen, Übernahmen

LVMH to Sell Marc Jacobs Fashion Brand to WHP, G-III Apparel -- 2nd Update

14. Mai 2026, 22:27 UTC

Akquisitionen, Fusionen, Übernahmen

LVMH Selling Marc Jacobs Fashion Brand to WHP, G-III Apparel -- Update

14. Mai 2026, 22:12 UTC

Ergebnisse

Applied Materials Raises Outlook as Semiconductor Equipment Demand Grows -- 2nd Update

14. Mai 2026, 21:52 UTC

Akquisitionen, Fusionen, Übernahmen

LVMH to Sell Marc Jacobs

15. Mai 2026, 00:00 UTC

Ergebnisse

Honda's Never Faced a Crisis Like This -- And a Comeback Won't Be Easy -- WSJ

14. Mai 2026, 23:57 UTC

Akquisitionen, Fusionen, Übernahmen

Kakao: Stake Sales Aim to Secure Funds for Future Investments

14. Mai 2026, 23:56 UTC

Akquisitionen, Fusionen, Übernahmen

Kakao: Share Sale to Lower Kakao Investment's Stake in Dunmau to 4.03%

14. Mai 2026, 23:56 UTC

Akquisitionen, Fusionen, Übernahmen

Kakao: Affiliate Kakao Investment to Sell 2.3M Dunamu Shares on June 15

14. Mai 2026, 23:56 UTC

Market Talk

Gold Prices Rise on Strong Demand -- Market Talk

14. Mai 2026, 23:56 UTC

Akquisitionen, Fusionen, Übernahmen

Kakao to Sell 6.55% Stake in Crypto Exchange Operator Dunamu to Hana Financial for KRW1.003T

14. Mai 2026, 23:50 UTC

Market Talk

Global Equities Roundup: Market Talk

14. Mai 2026, 23:50 UTC

Market Talk

Nikkei May Rise as AI Enthusiasm Continues -- Market Talk

14. Mai 2026, 23:47 UTC

Ergebnisse

JSW Steel: Prolonged Supply-Chain Disruptions Due to Middle East Crisis Pose Risk to Growth >500228.BY

14. Mai 2026, 23:47 UTC

Ergebnisse

JSW Steel Results Supported by Higher Steel Prices, One-Off Divestment Gains >500228.BY

14. Mai 2026, 23:46 UTC

Ergebnisse

JSW Steel 4Q Net INR163.7B Vs. Net INR21.39B >500228.BY

14. Mai 2026, 23:46 UTC

Ergebnisse

JSW Steel 4Q Rev INR511.8B Vs. INR448.19B >500228.BY

14. Mai 2026, 23:28 UTC

Market Talk

New Zealand's Economy Faltering Amid Shocks -- Market Talk

14. Mai 2026, 23:00 UTC

Market Talk

Australia's One Nation Party Leads In The Polls -- Market Talk

14. Mai 2026, 22:46 UTC

Market Talk

Global Equities Roundup: Market Talk

14. Mai 2026, 22:46 UTC

Market Talk

Court Decision 'Negative But Balanced' for Coles -- Market Talk

14. Mai 2026, 22:46 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

14. Mai 2026, 22:35 UTC

Market Talk

Fed's Warsh Talks Big Game; Will Focus On Credibility First -- Market Talk

14. Mai 2026, 22:11 UTC

Akquisitionen, Fusionen, Übernahmen

LVMH Agrees to Sell Marc Jacobs -- WSJ

14. Mai 2026, 22:06 UTC

Market Talk

Applied Materials Gets Improved Visibility into Customer Orders -- Market Talk

14. Mai 2026, 22:04 UTC

Ergebnisse

Thai Beverage Results Supported by Higher Contributions From Spritis Business >Y92.SG

14. Mai 2026, 22:04 UTC

Ergebnisse

Thai Beverage 2Q Net THB7.37B Vs. Net THB6.74B >Y92.SG

14. Mai 2026, 22:04 UTC

Ergebnisse

Thai Beverage 2Q Rev THB86.52B Vs. THB85.35B >Y92.SG

14. Mai 2026, 22:00 UTC

Ergebnisse

Xanadu Quantum Revenue Increases Fourfold. Why the Stock Is Falling. -- Barrons.com

14. Mai 2026, 21:55 UTC

Ergebnisse

Nu Holdings 1Q EPS 18c >NU

14. Mai 2026, 21:55 UTC

Ergebnisse

Nu Holdings 1Q Rev $4.97B >NU

Peer-Vergleich

Kursveränderung

Guardant Health Inc Prognose

Kursziel

By TipRanks

30.88% Vorteil

12-Monats-Prognose

Durchschnitt 128.88 USD  30.88%

Hoch 175 USD

Tief 92 USD

Basierend auf 19 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Guardant Health Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Starkes Kaufsignal

19 ratings

18

Buy

1

Halten

0

Sell

Technischer Score

By Trading Central

38.86 / 47.41Unterstützung & Widerstand

Kurzfristig

Very Strong Bearish Evidence

Mittelfristig

Bearish Evidence

Langfristig

Bullish Evidence

Stimmung

By Acuity

171 / 346 Ranking in Gesundheitswesen

Nachrichtenstimmung

Neutral

Volatilität

Unterdurchschnittlich

Nachrichtenvolumen (RCV)

Durchschnitt

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über Guardant Health Inc

Guardant Health, Inc., a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers. It offers Shield Test; Guardant Reveal Test for adjuvant treatment selection in early-stage cancer patients; Smart Liquid Biopsy Platform; and Guardant Galaxy, an AI-backed digital pathology platform that helps improve cancer biomarker detection. In addition, the company offers development services, including companion diagnostic development and regulatory approval, clinical study setup, monitoring and maintenance, testing development and support, technologies licensing, and kits fulfillment. The company has a collaboration agreement with Illumina, Inc. for the sharing of specimen samples to advance cancer research; and with ConcertAI to form first data-as-a-service that integrates clinical and tumor profiling data to accelerate cancer therapy research and development. The company was incorporated in 2011 and is headquartered in Palo Alto, California.
help-icon Live chat